Drugs / HCP1306
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07297693 | Dec 2025 → Mar 2026 overdue | — | Hanmi Pharmaceutical Company Limited | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06518122 | Sep 2024 → Jan 2025 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02941848 | Nov → Dec 2014 | hyperlipoproteinemia | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02941848 ↗ |
| Route | Oral | “Oral Administration” NCT07297693 ↗ |